These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 33268471)

  • 1. Late onset depression: dopaminergic deficit and clinical features of prodromal Parkinson's disease: a cross-sectional study.
    Kazmi H; Walker Z; Booij J; Khan F; Shah S; Sudre CH; Buckman JEJ; Schrag AE
    J Neurol Neurosurg Psychiatry; 2021 Feb; 92(2):158-164. PubMed ID: 33268471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder.
    Meles SK; Vadasz D; Renken RJ; Sittig-Wiegand E; Mayer G; Depboylu C; Reetz K; Overeem S; Pijpers A; Reesink FE; van Laar T; Heinen L; Teune LK; Höffken H; Luster M; Kesper K; Adriaanse SM; Booij J; Leenders KL; Oertel WH
    Mov Disord; 2017 Oct; 32(10):1482-1486. PubMed ID: 28734065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An
    Joling M; Vriend C; Raijmakers PGHM; van der Zande JJ; Lemstra AW; Berendse HW; Booij J; van den Heuvel OA
    Neuroimage Clin; 2019; 22():101755. PubMed ID: 30884365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical profiles of late-onset psychiatric patients exhibiting incidental REM sleep without atonia.
    Fujishiro H; Okuda M; Iwamoto K; Miyata S; Torii Y; Iritani S; Ozaki N
    J Neural Transm (Vienna); 2019 Aug; 126(8):1095-1104. PubMed ID: 31230267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.
    Pont-Sunyer C; Tolosa E; Caspell-Garcia C; Coffey C; Alcalay RN; Chan P; Duda JE; Facheris M; Fernández-Santiago R; Marek K; Lomeña F; Marras C; Mondragon E; Saunders-Pullman R; Waro B;
    Mov Disord; 2017 May; 32(5):726-738. PubMed ID: 28370517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of texture analysis to DAT SPECT imaging: Relationship to clinical assessments.
    Rahmim A; Salimpour Y; Jain S; Blinder SA; Klyuzhin IS; Smith GS; Mari Z; Sossi V
    Neuroimage Clin; 2016; 12():e1-e9. PubMed ID: 27995072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine reuptake transporter-single-photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease.
    Noyce AJ; Dickson J; Rees RN; Bestwick JP; Isaias IU; Politis M; Giovannoni G; Warner TT; Lees AJ; Schrag A
    Mov Disord; 2018 Mar; 33(3):478-482. PubMed ID: 29380907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease.
    Doppler K; Jentschke HM; Schulmeyer L; Vadasz D; Janzen A; Luster M; Höffken H; Mayer G; Brumberg J; Booij J; Musacchio T; Klebe S; Sittig-Wiegand E; Volkmann J; Sommer C; Oertel WH
    Acta Neuropathol; 2017 Apr; 133(4):535-545. PubMed ID: 28180961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constipation is not associated with dopamine transporter pathology in early drug-naïve patients with Parkinson's disease.
    Pagano G; Yousaf T; Wilson H; Niccolini F; Polychronis S; Chaudhuri KR; Politis M
    Eur J Neurol; 2018 Feb; 25(2):307-312. PubMed ID: 29078029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower
    Joling M; Vriend C; van der Zande JJ; Lemstra AW; van den Heuvel OA; Booij J; Berendse HW
    Neuroimage Clin; 2018; 19():130-136. PubMed ID: 30035010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease.
    Ransmayr G; Seppi K; Donnemiller E; Luginger E; Marksteiner J; Riccabona G; Poewe W; Wenning GK
    Eur J Nucl Med; 2001 Oct; 28(10):1523-8. PubMed ID: 11685496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort.
    Jennings D; Siderowf A; Stern M; Seibyl J; Eberly S; Oakes D; Marek K;
    JAMA Neurol; 2017 Aug; 74(8):933-940. PubMed ID: 28595287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct dopaminergic abnormalities in traumatic brain injury and Parkinson's disease.
    Jenkins PO; Roussakis AA; De Simoni S; Bourke N; Fleminger J; Cole J; Piccini P; Sharp D
    J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):631-637. PubMed ID: 32381639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The usefulness of combined brain perfusion single-photon emission computed tomography, Dopamine-transporter single-photon emission computed tomography, and
    Kobayashi S; Makino K; Hatakeyama S; Ishii T; Tateno M; Iwamoto T; Tsujino H; Kawasaki K; Mikuni K; Ukai W; Murayama T; Hashimoto E; Utsumi K; Kawanishi C
    Psychogeriatrics; 2017 Jul; 17(4):247-255. PubMed ID: 28130808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions.
    Park SB; Kwon KY; Lee JY; Im K; Sunwoo JS; Lee KB; Roh H; Ahn MY; Park S; Kim SJ; Oh JS; Kim JS
    Neurol Sci; 2019 Feb; 40(2):311-317. PubMed ID: 30415448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine Transporter, Age, and Motor Complications in Parkinson's Disease: A Clinical and Single-Photon Emission Computed Tomography Study.
    Palermo G; Giannoni S; Frosini D; Morganti R; Volterrani D; Bonuccelli U; Pavese N; Ceravolo R
    Mov Disord; 2020 Jun; 35(6):1028-1036. PubMed ID: 32154947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal Change of DAT SPECT in Parkinson's Disease and Multiple System Atrophy.
    Sakakibara S; Hashimoto R; Katayama T; Kenjyo M; Yokokawa Y; Saito Y; Hirakawa A; Ito M; Nakamura T; Hara K; Hashizume A; Aiba I; Inukai A; Katsuno M
    J Parkinsons Dis; 2020; 10(1):123-130. PubMed ID: 31707374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between dopaminergic dysfunction and anxiety in de novo Parkinson's disease.
    Picillo M; Santangelo G; Erro R; Cozzolino A; Amboni M; Vitale C; Barone P; Pellecchia MT
    Parkinsonism Relat Disord; 2017 Apr; 37():106-110. PubMed ID: 28214265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relations of clinical symptoms with dopamine transporter imaging in drug-naïve Parkinson's disease.
    Mito Y; Yabe I; Yaguchi H; Sato C; Takei T; Terae S; Tajima Y
    Clin Neurol Neurosurg; 2020 Sep; 196():105960. PubMed ID: 32593043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.